Shanghai Raas Blood Products002252.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Shanghai Raas Blood Products (002252.SZ) trades at a P/E of 26.50x, P/B of 0.99x, P/S of 4.99x, and a dividend yield of 0.99%.
Longitudinal percentile comparison: P/E sits at the 38th percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 34th percentile within its industry and the 36th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.47%, ranking at the 92nd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 36.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 0.99% comes from cash dividends, with an implied ~1.48% from buybacks — a fairly balanced mix of both channels. Shanghai Raas Blood Products operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002252 · SZSE: 002252 · 002252
Want the full picture on whether Shanghai Raas Blood Products (002252.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 26.50 | ||||||
| P/B (MRQ) | 0.99 | ||||||
| P/S (TTM) | 4.99 | ||||||
| Dividend Yield | 0.99% | ||||||
| Buyback + Div Yield | 2.47% |